Generic Name and Formulations:
Pioglitazone (as HCl), glimepiride; 30mg/2mg, 30mg/4mg; tabs.
Takeda Pharmaceuticals USA, Inc.
Indications for DUETACT:
Adjunct to diet and exercise in type 2 diabetes in patients already on pioglitazone + a sulfonylurea, or in patients on either pioglitazone or a sulfonylurea who need additional glycemic control.
Limitations Of use:
Not for treating type 1 diabetes or diabetic ketoacidosis.
Individualize. Take with first main meal of the day. Previously on glimepiride, or glimepiride + pioglitazone: Initially one 30mg/2mg or one 30mg/4mg tab once daily. Previously on pioglitazone, or pioglitazone + other sulfonylurea: initially one 30mg/2mg tab once daily. Patients with systolic dysfunction: use lowest Duetact dose after titration from pioglitazone 15–30mg has been tolerated. Concomitant insulin or sulfonylurea: reduce dose of these if needed. Concomitant strong CYP2C8 inhibitors: max pioglitazone 15mg daily. Concomitant colesevelam: give dose at least 4hrs prior to colesevelam.
NYHA Class III or IV heart failure. Sulfonamide allergy.
Symptomatic HF: not recommended. Monitor for signs/symptoms of CHF; discontinue or reduce dose if occurs. Edema. Glimepiride: potential increased risk of cardiovascular mortality. Hepatic disease. Monitor liver function before initiating therapy; if abnormalities detected, interrupt and assess probable cause; do not restart if ALT >3XULN with total bilirubin >2XULN. Routine monitoring LFTs during therapy without liver disease: not recommended. Active bladder cancer: not recommended. Prior history of bladder cancer: consider glycemic control benefits vs risk of cancer recurrence. Risk of fractures (esp. females). Stress. Elderly, debilitated, uncompensated strenuous excercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. G6PD deficiency: consider non-sulfonylurea alternative. Renal impairment. Perform regular eye exams. Resumption of premenopausal ovulation in anovulatory women may occur (may result in unintended pregnancy). Pregnancy. Nursing mothers.
Pioglitazone potentiated by CYP2C8 inhibitors (eg, gemfibrozil). Antagonized by CYP2C8 inducers (eg, rifampin) or topiramate (monitor for adequate glycemic control). Antagonizes oral midazolam. Monitor for heart failure with insulin. Glimepiride potentiated by highly protein-bound drugs, NSAIDs, fluoxetine, aspirin, salicylates, chloramphenicol, sulfonamides, coumarins, probenecid, MAOIs, β-blockers (monitor for hypoglycemia). Severe hypoglycemia with oral miconazole. May be antagonized by diuretics, corticosteroids, phenothiazines, thyroid drugs, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, isoniazid, colesevelam. May be affected by CYP2C9 substrates (eg, fluconazole, rifampin); monitor.
Thiazolidinedione + sulfonylurea.
Hypoglycemia, upper respiratory tract infection, accidental injury, weight gain, edema, headache, UTIs, GI upset; macular edema, hypersensitivity reactions (eg, angioedema, Stevens-Johnson syndrome); discontinue if occurs.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|